Overview

A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)

Status:
Recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

Trial Subjects (patients), will receive single infusions of pembrolizumab every 3 weeks until disease progression or unacceptable toxicity develops. They will receive radiotherapy at week 12.

Phase:

Phase 2

Details

Lead Sponsor:

University College, London

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab